RESEARCH ARTICLE

Interleukin-7 Enhances the in Vivo Anti-tumor Activity of Tumor-reactive CD8+ T cells with Induction of IFN-gamma in a Murine Breast Cancer Model

Chun-Hui Yuan1, Xue-Qin Yang2, Cheng-Liang Zhu3, Shao-Ping Liu4, Bi-Cheng Wang1, Fu-Bing Wang1*

Abstract

Interleukin-7 (IL-7) is a potent anti-apoptotic cytokine that enhances immune effector cell functions and is essential for lymphocyte survival. While it known to induce differentiation and proliferation in some haematological malignancies, including certain types of leukaemias and lymphomas, little is known about its role in solid tumours, including breast cancer. In the current study, we investigated whether IL-7 could enhance the in vivo antitumor activity of tumor-reactive CD8+ T cells with induction of IFN-γ in a murine breast cancer model. Human IL-7 cDNA was constructed into the eukaryotic expression plasmid pcDNA3.1, and then the recombinational pcDNA3.1-IL-7 was intratumorally injected in the TM40D BALB/C mouse graft model. Serum and intracellular IFN-γ levels were measured by ELISA and flow cytometry, respectively. CD8+ T cell-mediated cytotoxicity was analyzed using the MTT method. Our results showed that IL-7 administration significantly inhibited tumor growth from day 15 after direct intratumoral injection of pcDNA3.1-IL-7. The anti-tumor effect correlated with a marked increase in the level of IFN-γ and breast cancer cells-specific CTL cytotoxicity. In vitro cytotoxicity assays showed that IL-7-treatment could augment cytolytic activity of CD8+ T cells from tumor bearing mice, while anti-IFN-γ blocked the function of CD8+ T cells, suggesting that IFN-γ mediated the cytolytic activity of CD8+ T cells. Furthermore, in vivo neutralization of CD8+ T lymphocytes by CD8 antibodies reversed the antitumor benefit of IL-7. Thus, we demonstrated that IL-7 exerts anti-tumor activity mainly through activating CD8+ T cells and stimulating them to secrete IFN-γ in a murine breast tumor model. Based on these results, our study points to a potential novel way to treat breast cancer and may have important implications for clinical immunotherapy.

Keywords: Interleukin-7 - breast cancer - CD8+ T cells - IFN-γ - anti-tumor activity

Asian Pac J Cancer Prev. 15 (1), 265-271

Introduction

Cytokines are molecular messengers that allow the immune effector cells to communicate with one another to generate a coordinated, robust, but self-limited response to a target antigen (Lee et al., 2011). Over the past two decades, the growing interest in harnessing the immune system to eradicate cancer has been accompanied by heightened efforts to characterize cytokines and exploit their vast signaling networks to develop cancer treatments (Pellegrini et al., 2010). Cytokines directly stimulate immune effector cells and stromal cells at the tumor site and enhance tumor cell recognition by cytotoxic effector cells, and are crucial for the survival and proliferation of a broad range of T lymphocytes, resulting in the maintenance of a polyclonal naïve T cell pool with the ability to respond to tumors (Klebanoff et al., 2004; Lee et al., 2011). Numerous animal tumor model studies have demonstrated that cytokines have broad anti-tumor activity and this has been translated into a number of cytokine-based approaches for cancer therapy (Krawczenko et al., 2005). Recent years have seen a number of cytokines, including GM-CSF, IL-2, IL-12, IL-15, IL-18 and IL-21, from bench to clinical trials, have been used for patients with advanced cancer (Krawczenko et al., 2005; Li et al., 2007).

IL-7 is a single-chain protein of 19 kDa produced predominantly by bone marrow and lymphoid stromal cells, which belongs to a type I short-chain cytokine of the hematopoietin family, a group that also includes IL-2, IL-3, IL-4, IL-5, GM-CSF, IL-9, IL-13,IL-15, and M-CSF (Li et al., 2007; Liu et al., 2007). It was first recognized as a protein with growth promoting effects on B-cell progenitors in vitro and later for its critical role in
lymphopoiesis. Recently, it has been termed an “immuno-regenerative cytokine” recognizing its modulatory role in peripheral T-cell homeostasis (Fry et al., 2002; Krawczenko et al., 2005). The biological effects of IL-7 on target cells are mediated by binding to the high-affinity IL-7 receptor complex that is composed of the ligand binding IL-7 receptor α-chain and the common shared γ-chain (Vudattu et al., 2007). Naïve T cells express high levels of the IL-7 receptor CD127 and respond rapidly to IL-7 stimulation, making this molecule an attractive agent for restoration of T cell activities in tumor-bearing hosts. For the recent years, IL-7 has been widely used as an immunotherapy for inflammation and tumor as for its multi-biological property (Appasamy, 1999; Krawczenko et al., 2005; Pellegrini et al., 2010; Lundstrom et al., 2012), functions as a pro-pro-B cell growth-stimulating factor, inducing proliferation of CD4/CD8 subtype in thymus, stimulating the differentiation of PBMC into LAK cells. There are several reports from both murine and human studies describing the anti-tumor activity of IL-7. In lung cancer-bearing mice (Andersson et al., 2009), IL-7 treatment led to marked reduction in tumor burden with extensive lymphocytic infiltration of the tumors and enhanced survival. The antitumor responses were accompanied by the enhanced elaboration of IFN-γ and the IFN-γ inducible CXCR3 targeting antiangiogenic chemokines CXCL9 and CXCL10. In melanoma-bearing mice (Wu et al., 1993; Krawczenko et al., 2005), after treatment with IL-7 in combination with local hyperthermia, the maximal anti-tumor effect was reached. The anti-tumor effect was also observed in patients with metastatic melanoma. The application of exogenous IL-7 augmented LAK cell proliferation and activity. Interleukin-7 cDNA transferred in non-small-cell lung cancer decreases tumor proliferation (Sharma et al., 1996), modifies cell surface molecule expression, and enhances antitumor reactivity. However, little is known about the antitumor effects of IL-7 against breast cancer. An understanding of the cellular mechanism of IL-7-mediated anti-breast cancer responses will enable the design of strategies for its optimum utility in tumor control.

In this study, we investigated the relative mechanism involved in how IL-7 performed antitumor activity in a murine breast tumor model. Our results demonstrated that the tumor growth was significantly inhibited following IL-7 administration to mice bearing breast cancer from day 15 after direct intratumoral injection of pcDNA3.1-IL-7. Accompanying the in vivo antitumor responses of IL-7 administration was marked by increasing the level of IFN-γ and enhancing CTLs cytotoxicity. IL-7 administration could augment cytolytic activity of CD8+ T cells from mice bearing breast tumor, however, antibody to IFN-γ neutralized the cytolytic activity of CD8+ T cells. Furthermore, in vivo neutralization of CD8+ T lymphocytes by CD8 antibody reversed the anti-tumor benefit of IL-7. The neutralization to IFN-γ and depletion of CD8+ T cells demonstrated that the in vivo mechanism underlying the anti-tumor effects of this regimen was partly dependent on the production of IFN-γ by the CD8+ T cells and not their direct cytotoxic capability.

IL-7 Eukaryotic Vector Construction, Transient transfection, and Expression

The human IL-7 expressing vector construction was according to previous articles. IL-7 cDNA (GenBank: accession, BC047698) was amplified and subcloned in-frame between the HindIII and EcoRI restriction sites of pcDNA3.1 (+/−Myc-His A (designated as pcDNA3.1). The construction was confirmed by restriction enzyme digestions and DNA sequencing analysis. The primer sequences were (forward) 5'-GGATCCAAACTCTTATGTTCCATGGTCTTTT-3' and (reverse) 5'-CCGGATCTATTATACGCTGCCCTTCA-3', where the underlined oligonucleotides represent EcoRI and HindIII sites, respectively, to facilitate cloning. cDNA encoding human IL-7 was obtained by reverse transcription and PCR amplification of RNA derived from the human peripheral blood. Murine TM40D cells were grown in 75 mm2 flasks and transfected with 5 μg of pcDNA3.1, pcDNA3.1-IL-7 (designated as pcDNA3.1-IL-7), detailed steps according to LipofectamineTM2000 (Invitrogen) manual. After 48 h of incubation at 37°C in a CO2 incubator, cell supernatants were collected and analyzed by SDS-PAGE and Western blot.

Model Construction of Mice Bearing Breast Tumor and Evaluation of Local Tumor Growth

TM40D cells in the exponential growth phase were harvested and washed in PBS, before in vivo injection, their viability exceeded 95%, as determined by trypan blue staining. To induce localized tumors, syngeneic BALB/c mice were subcutaneously (s.c.) challenged into the forth mammary Gland with 1×106 TM40D breast cancer cells (Murphy et al., 1993). The indicated doses (100 μg/100 μl) of pcDNA3.1, pcDNA3.1-IL-7 and/or PBS were then injected s.c. into the tumor injection site at day 5, and then stimulated by gene pulse transfection apparatus. Tumor size was determined every other day in 30-day interval with caliper, and the tumor volume in mm3 was calculated by the formula: Volume = (width)2×length/2.
Interleukin-7 Enhances in Vivo Anti-tumor Activity of Tumor-reactive CD8+ T cells in a Murine Breast Cancer Model

In vitro Cytotoxicity Assay

Target cells (TM40D) were prepared at 4×10⁵/ml. CD8+ T cells were isolated from splenocytes of treated mice, set 3 longitudinal groups to obtain effector-target ratios from 25:1 to 100:1, then 100µl of each cell solution was placed in triplicates into 96-well plate and incubated 48h. TM40D cells and CD8+ T cells each alone was simultaneously seeded as two control groups. As for pcDNA3.1-IL-7 + anti-IFN-γ group, upon cells co-cultured, IFN-γ secretion was blocked by mouse IFN-gamma mAb (5 µg/ml, Clone H22, R&D Systems), and CD8+ cells kill activity was detected by MTT method. Counted cell killed percentage (%) by using the formula: lysis percentage (%) = [1-(experimental OD – CD8+ T cells OD)/ TM40D cells OD] × 100.

In vivo CD8+ T cells Depletion Assay

Set three groups of mouse model (6 mice/group), PBS, pcDNA3.1-IL-7 + CD8 Ab Isotype and pcDNA3.1-IL-7 + Anti-CD8 (CD8 Antibody), respectively. And for pcDNA3.1-IL-7 + anti-CD8 group or pcDNA3.1-IL-7 + CD8 Ab Isotype group, mice were intravenously injected with anti-CD8 mAb (clone 2.43; BD Bioscience, 250 µg/mouse) or CD8 Ab Isotype (Rat IgG2a, κ) 24h before plasmid treatment. Tumor size (volume) was determined every other day in 30-day interval.

Statistical Analysis

The data were analyzed using Prism 5.0 software (GraphPad). Experiments were repeated three times. The data presenting the differences between the groups were analyzed by one-way or two way ANOVA with Bonferroni post-test to compare tumor volume in the treatment groups. P < 0.05 indicated that the value of the test sample was significantly different from that of the relevant controls.

Results

Construction of recombinant pcDNA-3.1-IL-7 plasmid and IL-7 expression in murine TM40D cells

To construct the recombinant plasmids, the DNA fragment of the entire IL-7 gene sequence from splenocytes was amplified and cloned into the eukaryotic expression vector pcDNA3.1. Restriction enzyme digestion analysis (Figure 1A) showed that the relative molecular mass (Mr) of each inserted DNA fragment was identical to the value predicted. Recombinant plasmid was then transient transfected into TM40D cells, harvested cells after 48h. IL-7 expression was determined by western-blotting. Western blot analysis showed that IL-7 was expressed by TM40D cells (Figure 1B).

IL-7 significantly inhibited mouse breast tumor growth

To determine whether IL-7 has anti-tumor activity, the mice were treated with 100µg/100µl of pcDNA3.1(control vehicle), pcDNA3.1-IL-7 or PBS by using direct intratumoral injection at day 5 after TM40D cells injection; tumor size was then determined every day in 30-day interval. As shown in (Figure 2), tumor growth of
pcDNA3.1-IL-7 treated group was significantly inhibited since day 15 when compared with control groups. This result demonstrates that IL-7 was effective against TM40D-induced breast tumor.

Increased serum IFN-γ level in IL-7-treated tumor bearing mice

IFN-γ is a cytokine whose biological activity is conventionally associated with cytostatic/cytotoxic and anti-tumor mechanisms during cell-mediated adaptive immune response, and plays an important role in the host response to restrict tumor growth, so we examined the effect of exogenous IL-7 administration on IFN-γ secretion in tumor-bearing mice. The levels of serum IFN-γ was measured 30 days after mice were injected with breast tumor cells TM40D via s.c. ELISA analysis showed that serum IFN-γ levels were significantly increased in the pcDNA3.1-IL-7-treated group (242.3±10.1 pg/ml) (\( p < 0.05 \), Figure 3) compared to the pcDNA3.1 empty vector group (133.6±9.4 pg/ml) or PBS-treated group. Data shown are mean±SD from six independent experiments.

Table 1. IL-7 Augments IFN-γ-mediated CD8+ T Cells Cytolytic Activity (Cytotoxic assay analyzed by MTT method)

<table>
<thead>
<tr>
<th>Groups</th>
<th>E:T=25:1</th>
<th>E:T=50:1</th>
<th>E:T=100:1</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>5.2±0.6</td>
<td>6.8±0.9</td>
<td>7.7±1.1</td>
</tr>
<tr>
<td>pcDNA3.1</td>
<td>5.9±0.9</td>
<td>7.6±1.2</td>
<td>8.5±1.6</td>
</tr>
<tr>
<td>pcDNA3.1-IL-7</td>
<td>18.6±1.9</td>
<td>27.3±2.4</td>
<td>38.3±3.6</td>
</tr>
<tr>
<td>pcDNA3.1-IL-7 + anti-IFN-γ</td>
<td>7.8±0.9</td>
<td>9.3±1.2</td>
<td>12.2±1.5</td>
</tr>
</tbody>
</table>

\( ^* \text{pcDNA3.1-IL-7 v.s. pcDNA3.1, pcDNA3.1-IL-7 + anti-IFN-γ or PBS groups, } p < 0.05 \).

IL-7 augments CD8+ T cells cytolytic activity

The above results suggest that IL-7 inhibits local tumor growth, and stimulates IFN-γ secretion in serum...
T cells to secrete IFN-γ, and then IFN-γ 

T cells, so we wondered whether

T cells when previously

tumor size was more visible

T cells, NK cells and Macrophage

component which IL-7 employed to anti-tumor. 24h before

plasmid treatment. Mean tumor

size in each mouse group was quantified every other day. Bars, SD. The mean tumor size in pcDNA3.1-IL-7 + CD8 Ab isotype mouse group was significantly smaller than that in PBS group or pcDNA3.1-IL-7 + anti-CD8 group (*p < 0.05) from day 15 to 28.

or produced by CD8+ T cells, so we wondered whether

IL-7 could enhance CD8+ T cells cytolytic activity. Ex vivo cytotical assays showed that CD8+ T cells from IL-7-treated group had higher levels of cytotic activity compared with control group at the same E/T ratio. Cytotical activity of CD8+ T cells was more visible along with E/T ratio increased, especially when E/T was 100:1. However, anti-IFN-γ could block cytotical activity performed by CD8+ T cells when previously incubated with it (Table 1 and Figure 5). So we could draw a conclusion that IL-7 inhibits breast tumor growth by inducing CD8+ T cells to secrete IFN-γ, and then IFN-γ performed its anti-tumor activity directly or indirectly by mediated CD8+ T cells cytotic activity.

In vivo injected CD8 Ab reversed IL-7 anti-tumor activity

In order to figure out whether CD8+ T cell is a major component which IL-7 employed to anti-tumor. 24h before

cDNA3.1-IL-7 injection, mice were injected with CD8 mAb (250μg/mice) or Iso-type IgG control, and then measured tumor size according to previous schedule. We observed that anti-CD8-treatment reversed the inhibitory role of IL-7 in tumor growth, a significant difference of tumor size was noticed when compared anti-CD8-treatment with Iso-type from day 15 to day 28 (Figure 6). So we also confirmed that CD8+ T cells play important role in antitumor and is consistent with previous reports (Tanaka et al., 1999).

Discussion

The potential for IL-7 to expand the naive T cell pool and memory cell pool by driving homeostatic expansion, could be applied therapeutically (Rosenberg et al., 2006). Using this rationale, studies have been performed to evaluate whether IL-7 can increase the number of responding T cells and improve anti-tumor immune responses (Krawczenko et al., 2005; Yang et al., 2005). Three main immunotherapeutic approaches have been used to evaluate IL-7 anti-tumor immunity, the vaccine strategies, adoptive transfer of tumor specific T cell therapy strategies and the gene transfer therapy strategies. Several studies have been used to use IL-7 as an adjuvant together with vaccines to evaluate anti-tumor immunity in a lymphopenic environment (Krawczenko et al., 2005; Pellegrini et al., 2009). IL-7 and IL-15 are known to be increased under lymphopenic conditions, and studies have shown both using vaccine strategies and adoptive T cell therapy strategies (Rubinstein et al., 2008).

Several investigators have used gene transfer techniques to increase local production of IL-7 in tumor cells or within the tumor microenvironment (Krawczenko et al., 2005). IL-7 gene transfer enhances the immune response to tumor cells and can support tumor regression. Finke et al. (Finke et al., 1998) applied adenovirus-enhanced CD3 receptor-mediated IL-7 gene transfer in SCID mouse bearing human lymphoma. An episomally replicating plasmid containing human IL-7 cDNA under the control of a cytomegalovirus promoter was used for transfecting cytokine-induced killer (CIK) cells (Pellegrini et al., 2011). A report (Sharma et al., 2003) described the intratumoral administration of IL-7 gene-modified DCs. Another group (Verhoeven et al., 2003) described the application of lentiviral vectors for IL-7 gene transfer into resting primary T lymphocytes.

As considered that tumor vaccine produced by ex vivo way is complicated and time consuming, even more, viral vector application have the possibility influenced by viral replication and immune reaction mediated by recipient (Anderson et al., 2007), we adopted simple and effective gene-treatment by direct intratumoral injection of pcDNA3.1-IL-7 in the TM40D BALB/C mice grafts model to evaluate the antitumor effect of IL-7. From day 15 after direct intratumoral injection of pcDNA3.1-IL-7, IL-7 significantly inhibited tumor growth compared with empty vector pcDNA3.1 or PBS treatment. This result is in agreement with the previous studies about IL-7 antitumor activities.

IFN-γ, which is mainly produced by T cells and NK cells, plays a major role in the antitumor activity (Zaidi et al., 2011). The expression of serum and intracellular IFN-γ were detected in our study. Accompanying the anti-breast cancer responses of IL-7-treament were increases the level of IFN-γ. Compared with PBS or empty vector pcDNA3.1 group, IL-7 administration group significantly stimulated IFN-γ production. In order to figure out the types of immune cells producing IFN-γ following IL-7-treated mice, intracellular cytokine staining was used to analyze the percentage of IFN-γ-producing cells among CD4+ T cells, CD8+ T cells, NK cells and Macrophage (Mφ) in spleen. We found that IL-7 mainly induced CD4+ T cells and CD8+ T cells to secrete IFN-γ, but had minimal effect on NK cells and Mφ. In additoin to increased cytokine IFN-γ production, immuno-histochemistry analysis showed that tumor tissue was infiltrated by plenty of inflammatory cells, CD4+ T cells and CD8+ T cells. Many facets of T lymphocyte activities are suppressed.
thus allowing tumors to progress in immune-competent hosts (Jichia et al., 1991; Klebanoff et al., 2006; Andersson et al., 2009). Our results indicate that IL-7 treatment of breast cancer-bearing mice restores T cell activities and stimulates IFN-γ production. IL-7 treatment caused a significant reduction in tumor burden that correlated with increases in the CD8+ T cell population and stimulating them to secrete high level IFN-γ.

Cytotoxic T lymphocytes (CTLs) can play a prominent role in the anti-tumor immune responses of both mice and humans (Lynch et al., 1994). Many studies have demonstrated that γ-chain receptor cytokines, including IL-2, IL-7 and IL-15, act at different stages of the immune response to promote the survival, proliferation and effector function of CD8+ T cells (Strengell et al., 2003; Krawczenko et al., 2005; Andersson et al., 2009). IL-7 is critical for the homeostatic expansion of naive CD4+ and CD8+ T cells in immunodeficient hosts and can also mediate the survival of memory T cells (Roato et al., 2006).

IL-7 has been demonstrated to enhance both antitumour and anti-viral CTL as well as lymphokine-activated killer (LAK) activity (Unsinger et al., 2010). In this report, we studied the ability of IL-7 to support the activation of in vitro CD8+ T cell CTL present in spleen of breast cancer-bearing mice. We separated splenic T cells from each group as effector cells, and used TM40D cells as target cells to evaluate CD8+ T cells cytolytic activity in vitro. As showed in Table 1, compared with PBS or empty vector pcDNA3.1 group, CD8+ T cells from IL-7 treated tumor-bearing mice had enhanced cytolytic activity, especially when E:T (effector cells:target cells) ratio was 100:1. To explore whether the CTL direct by CD8+ T cells, the importance of IFN-γ was assessed in neutralization experiments. When anti-IFN-γ was added into the co-culture system, neutralization of IFN-γ partially reversed the antitumor benefit of IL-7. The neutralization of antibodies to IFN-γ demonstrated that in vitro mechanism underlying the antitumor effects of this regimen was partly dependent on both the production of IFN-γ by the CD8+ T cells and not their direct cytolytic capability.

T cells played a crucial role in the generation of an efficient IL-7-mediated anti-tumor immune response which is supported by the evidence from neutralization experiments (Ferrari et al., 1995; Geiselhart et al., 2001; Lai et al., 2011). With the aim of confirming the rolling part of CD8+ T cells more precisely, we depleted CD8+ T cells in vivo, and found that IL-7-treatment was not working well in controlling tumor growth, and IFN-γ level in sera decreased significantly. Neutralization of CD8+ T cells led to the complete reversal of the anti-tumor immune responses, indicating CD8+ T cell effectors for the full anti-tumor benefit of IL-7. As shown in Figure 6, after 28 days, tumor growth was inhibited in CD8+ T cells depleted mice bearing breast cancer, the possible reason maybe that cytokines have network effects, and IL-7 can function on another part of immune system like CD4+ T cells to inhibit tumor growth in an advanced stage (Lo et al., 2003; Terabe et al., 2004), or only as a result of the degradation of CD8 antibody. Those possibilities need to be further confirmed.

Taken together, the enhancement in IL-7-dependent anti-breast cancer immune responses requires both activated CD8+ T cells and high level IFN-γ to exert their cytolytic function. Though the fact that IL-7 significantly reduced tumor burden mainly dependent on CD8+ T cells to secret IFN-γ to perform their cytolytic function, there may be still have another ways for IL-7 to realize its antitumor capacity. Nevertheless, the findings from the current study may stimulate the development of an immunotherapeutic approach using IL-7 for the stimulation of adaptive immunity against breast cancer.

Acknowledgements

The authors thank members of their laboratory and their collaborators for their research work. This work was supported by National Natural Science Foundation of China (No. 58101485), and the major state basic research development 973 program (No.2010CB518900), and the key scientific research project of Hubei provincial department of education (No. D20126102).

The authors declare that they have no competing interests.

References


Interleukin-7 Enhances in Vivo Anti-tumor Activity of Tumor-reactive CD8+ T cells in a Murine Breast Cancer Model